Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms

In-Suk Kim; Ja Young Lee; Sun-Young Kong; Seung-Tae Lee; Jungwon Huh; Myung-Hyun Nam; Myungshin Kim; Young-Uk Cho; Hee-Jin Huh; Jeawoo Song; Hyosoon Park

doi:10.3343/lmo.2020.10.1.10

Journal List > Lab Med Online > v.10(1) > 1142044

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Lee, Kong, Lee, Huh, Nam, Kim, Cho, Huh, Song, and Park: Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms

Guideline

Laboratory Medicine Online 2020; 10(1): 10-24.

Published online: 27 December 2019

DOI: https://doi.org/10.3343/lmo.2020.10.1.10

Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms

In-Suk Kim, M.D.^1,^*, Ja Young Lee, M.D.^2,^*, Sun-Young Kong, M.D.³

, Seung-Tae Lee, M.D.⁴, Jungwon Huh, M.D.⁵, Myung-Hyun Nam, M.D.⁶, Myungshin Kim, M.D.⁷, Young-Uk Cho, M.D.⁸, Hee-Jin Huh, M.D.⁹, Jeawoo Song, M.D.⁴, Hyosoon Park, M.D.¹⁰

¹Department of Laboratory Medicine, Pusan National University School of Medicine, Yangsan, Korea.

²Department of Laboratory Medicine, Inje University College of Medicine, Busan, Korea.

³Department of Laboratory Medicine, National Cancer Center, Goyang, Korea.

⁴Department of Laboratory Medicine, Yonsei University School of Medicine, Seoul, Korea.

⁵Department of Laboratory Medicine, Ewha Womans University College of Medicine, Seoul, Korea.

⁶Department of Laboratory Medicine, Korea University School of Medicine, Seoul, Korea.

⁷Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

⁸Department of Laboratory Medicine, University of Ulsan College of Medicine, Seoul, Korea.

⁹Department of Laboratory Medicine, Dongkuk University Hospital, Seoul, Korea.

¹⁰Department of Laboratory Medicine, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Corresponding author: Sun-Young Kong, M.D., Ph.D. Department of Laboratory Medicine, Center for Diagnostic Oncology and Translational Epidemiology Research Branch, Hospital and Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea. Tel: +82-31-920-1735, Fax: +82-31-920-1339, ksy@ncc.re.kr

Equal contributor:

*These authors contributed equally as first authors.

Received 20 February 2019 Revised 24 April 2019 Accepted 8 May 2019

Laboratory Medicine Online

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The standardization committee of the Korean Society for Laboratory Hematology revised laboratory testing guidelines in order that hematologic neoplasms could be diagnosed according to the revised 4th edition of WHO classification of tumors of haematopoietic and lymphoid tissues. The new guidelines were revised based on an extensive review of international guidelines that included the National Comprehensive Cancer Network Guidelines, and European LeukemiaNet recommendations that are based on the revised WHO classification. We expect that the newly revised guidelines will improve clinical decisions, standardize laboratory tests, and enhance the development of new molecular technologies that are integrated into diagnostic algorithms via ongoing consensus initiatives.

Keywords: Hematologic neoplasms, Diagnosis, Laboratory testing, Guidelines

Figures and Tables

Table 1

chronic myeloid leukemia, BCR-ABL1-positive

Abbreviations: cCD3, cytoplasmic CD3; cCD22, cytoplasmic CD22; cCD79a, cytoplasmic CD79a.

Table 2

myeloproliferative neoplasms

Table 3

myelodysplastic/myeloproliferative neoplasms

Table 4

myelodysplastic syndrome

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; CMV, cytomegalovirus.

Table 5

acute leukemia

Table 6

plasma cell neoplasms

Table 7

lymphoma with bone marrow involvement

Abbreviations: MALT, mucosa-associated lymphoid tissue; EBV, Epstein-Barr virus.

Table 8

post-transplant lymphoproliferative disorder

Abbreviations: PH, plasmacytic hyperplasia; IM, infectious mononucleosis; FFH, florid follicular hyperplasia; PTLD, posttransplant lymphoproliferative disorders; EBV, Epstein-Barr virus.

Table 9

histiocytic neoplasm

References

1. Swerdlow SH, Campo E, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC;2017.

2. Lee JY, Kim HK, Huh J, Kim M, Kong SY, Cho YW, et al. Test guidelines for initial diagnosis of hematologic neoplasms. Lab Med Online. 2016; 6:1–7.

3. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018; 16:1108–1135.

4. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw. 2017; 15:1193–1207.

5. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15:60–87.

6. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017; 15:926–957.

7. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, et al. NCCN guidelines insights: Acute lymphoblastic leukemia, version 1.2017. J Natl Compr Canc Netw. 2017; 15:1091–1102.

8. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, et al. NCCN guidelines insights: Multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018; 16:11–20.

9. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, et al. NCCN guidelines insights: Non-Hodgkin's lymphomas, version 3.2016. J Natl Compr Canc Netw. 2016; 14:1067–1079.

10. Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, et al. NCCN guidelines insights: T-cell lymphomas, version 2.2018. J Natl Compr Canc Netw. 2018; 16:123–135.

11. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, et al. NCCN guidelines insights: Hodgkin lymphoma, version 1.2018. J Natl Compr Canc Netw. 2018; 16:245–254.

12. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129:424–447.

13. Heidel FH, Gale RP, Hochhaus A. Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Leukemia. 2018; 32:1055–1056.

SUPPLEMENTARY MATERIALS

Supplementary Table 1

Myeloid neoplasms with germline predisposition

Supplementary Table 2

Morphologic approach in mature B cell neoplasms

Supplementary Table 3

Morphologic approach in mature T cell neoplasms

TOOLS

ORCID iDs: Sun-Young Kong
https://orcid.org/0000-0003-0620-4058
Similar articles